ArticlePloS one2013
The TRPM6/EGF pathway is downregulated in a rat model of cisplatin nephrotoxicity.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 59 citations in OpenAlex.
- Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors in Cisplatin Nephrotoxicity: A Mechanistic Review.Kidney360 · 2026Review
- Supplementation with 2'-fucosyllactose, a prebiotic human milk oligosaccharide (HMO), in a magnesium-containing medical food reduces chemotherapy-induced mucositis in Wistar rats.Frontiers in nutrition · 2026Article
- From intracellular processing to renal phenotypes: a mechanism-informed framework for interpreting kidney injury and electrolyte patterns with antibody-drug conjugates in solid tumors.Frontiers in pharmacology · 2026Review
- The critical role of ion channels in kidney disease: perspective from AKI and CKD.Renal failure · 2025Review
- Cisplatin-induced Severe Renal Salt-wasting Syndrome Complicated with Hypovolemic Shock and Various Electrolyte Abnormalities in a Patient with Thymoma.Internal medicine (Tokyo, Japan) · 2025Article
- Cancer treatment-associated hypomagnesemia: Analysis from a large pharmacovigilance database.European journal of internal medicine · 2025Article
- The Clinical Spectrum of Acquired Hypomagnesemia: From Etiology to Therapeutic Approaches.Biomedicines · 2025Review
- Roles of TRPM channels in glioma.Cancer biology & therapy · 2024Review
- Predictive value of serum magnesium levels for prognosis in patients with non-small cell lung cancer undergoing EGFR-TKI therapy.Open life sciences · 2024Article
- Article
- Article
- Expression ofBiomolecules · 2021Article
- Epidermal growth factor as a potential prognostic and predictive biomarker of response to platinum-based chemotherapy.PloS one · 2021Article
- Electrolyte Disorders Induced by Antineoplastic Drugs.Frontiers in oncology · 2020Review
- Identifying cisplatin-induced kidney damage in paediatric oncology patients.Pediatric nephrology (Berlin, Germany) · 2018Review
- Identifying Therapeutic Targets for Sepsis Research: A Characterization Study of the Inflammatory Players in the Cecal Ligation and Puncture Model.Mediators of inflammation · 2018Article
- Renoprotective Effect of Platelet-Rich Plasma on Cisplatin-Induced Nephrotoxicity in Rats.Oxidative medicine and cellular longevity · 2018Article
- Indole-3-carbinol protects against cisplatin-induced acute nephrotoxicity: role of calcitonin gene-related peptide and insulin-like growth factor-1.Scientific reports · 2016Article
- Role of renal TRP channels in physiology and pathology.Seminars in immunopathology · 2016Review
- The role of calbindin-D28k on renal calcium and magnesium handling during treatment with loop and thiazide diuretics.American journal of physiology. Renal physiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cisplatin-induced hypomagnesemia is described in humans and rats, but the underlying mechanisms are still unclear. Recent studies have shown that epidermal growth factor (EGF) stimulates Mg(2+) re-absorption in the distal convoluted tubule via the Mg(2+) channel TRPM6. This study investigates the role of TRPM Mg(2+) channels, claudines, and EGF in the Mg(2+) homeostasis in a rat model of cisplatin-induced nephrotoxicity. Wistar rats were given 2.5 mg/kg cisplatin per week for 3 weeks and were euthanized 4 or 9 weeks after the first administration. The cisplatin treatment significantly increased the fractional excretion of Mg(2+). Real-time RT-PCR and/or Western blots were performed to assess the renal expression TRPM6, TRPM7, claudin-16, claudin-19, EGF, EGF receptor (EGFR) and EGFR-pathway components. The renal mRNA expression of TRPM6 and EGF showed a significant decrease after cisplatin treatment, while the TRPM7, claudin-16 and EGFR expressions remained stable. The claudin-19 mRNA expression was significantly upregulated after cisplatin treatment. Western blotting confirmed the mRNA expression data for the claudins, but an showed upregulation of EGFR only at week 9. The role of the EGFR pathway, involving Pi3-AKT-Rac1, in cisplatin-induced nephropathy, could not be substantiated in further detail. This study shows that cisplatin treatment results in EGF and TRPM6 downregulation in the rat kidney, causing renal Mg(2+) loss. Our results are in line with the hypothesis that EGF influences the renal expression or activation of TRPM6 and plays a significant role in Mg(2+) loss in medication-induced nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.